Neurocardiogenic syncope

British Medical Journal

Volumn 329, Issue 7461, 2004, Pages 336-341

  Chen Scarabelli, Carol ^a   Scarabelli, Tiziano M ^b  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DISOPYRAMIDE; FLUDROCORTISONE; METOPROLOL; MIDODRINE; NADOLOL; PAROXETINE; PROPANTHELINE BROMIDE; SCOPOLAMINE; SEROTONIN UPTAKE INHIBITOR;

CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DATA BASE; DIFFERENTIAL DIAGNOSIS; EDEMA; EXERCISE; HEART DISEASE; HEART FAILURE; HEART PROARRHYTHMIA; HUMAN; HYPERTENSION; INFORMATION PROCESSING; INSOMNIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PACEMAKER; PATIENT EDUCATION; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SYNCOPE; TILT TABLE TEST; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; URINE RETENTION; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 4043162641     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.329.7461.336     Document Type: Review

References (25)

1. American Heart Association. Syncope. www.americanheart.org/presenter. jhtml?identifier=4749 (accessed 30 Jan 2004).
2. Kapoor WN. Syncope. N Engl J Med 2000;343:1856-62.
3. White CM, Tsikouris JP. A review of pathophysiology and therapy of patients with vasovagal syncope. Pharmacotherapy 2000;20:158-65.
4. Brignole M, Alboni P, Benditt D, Bergfeldt L, Blanc JJ, Bloch Thomsen PE, et al for the Task Force on Syncope, European Society of Cardiology. Guidelines on management (diagnosis and treatment) of syncope. Eur Heart J 2001;22:1256-306.
5. Kenny RA. Neurally mediated syncope. Clin Geriatr Med 2002;18:191-210.
6. Benditt DG, Ferguson DW, Grubb BP, Kapoor WN, Kugler J, Lerman BB, et al. ACC expert consensus document: tilt table testing for assessing syncope. J Am Coll Cardiol 1996;28:263-75.
7. Fogoros RN. Practical cardiac diagnosis: electrophysiologic testing. 3rd ed. Maiden, MA: Blackwell Publishing, 1999.
8. Krediet CT, van Dijk N, Linzer M, van Lieshout JJ, Wieling W. Management of vasovagal syncope: controlling or aborting faints by leg crossing and muscle tensing. Circulation 2002;106:1684-9.
9. Lu CC, Diedrich A, Tung CS, Paranjape SY, Harris PA, Byrne DW, et al. Water ingestion as prophylaxis against syncope. Circulation 2003;108:2660-5.
10. Zaqqa M, Massumi A. Neurally mediated syncope. Tex Heart Institute J 2000;27:268-72.
11. Nair N, Padder FA, Kantharia BK. Pathophysiology and management of neurocardiogenic syncope. Am J Managed Care 2003;9:327-34.
12. Sutton R, Petersen ME. The clinical spectrum of neurocardiogenic syncope. J Cardiovasc Electrophysiol 1995;6:569-76.
13. Frishman WH, Azer V, Sica D. Drug treatment of orthostatic hypotension and vasovagal syncope. Heart Dis 2003;5:49-64.
14. Gregoratos G, Cheitlin M, Conill A, Epstein AE, Fellows C, Ferguson TB Jr, et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: executive summary - a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on pacemaker implantation). Circulation 1998;97:1325-35.
15. O'Mahony D. Pathophysiology of carotid sinus hypersensitivity in elderly patients. Lancet 1995;346:950-2.
16. Madrid AH, Ortega J, Rebollo JG, Manzano JG, Segovia JG, Sanchez A, et al. Lack of efficacy of atenolol for the prevention of neurally mediated syncope in a highly symptomatic population: a prospective, double-blind, randomized and placebo-controlled study. J Am Coll Cardiol 2001;37:544-9.
17. Flevari P, Livanis EG, Theodorakis GN, Zarvalis E, Mesiskli T, Kremastinos DT. Vasovagal syncope: a prospective, randomized, crossover evaluation of the effect of propranolol, nadolol and placebo on syncope recurrence and patients' well-being. J Am Coll Cardiol 2002;40:499-504.
18. Kaufmann H, Saadia D, Voustianiouk A. Midodrine in neurally mediated syncope: a double-blind, randomized, crossover study. Ann Neurol 2002;52:342-5.
19. Perez-Lugones A, Schweikert R, Parra S, Sra J, Akhtar M, Jaeger F, et al. Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study. J Cardiovasc Electrophysiol 2001;12:935-8.
20. Ward CR, Gray JC, Gilroy JJ, Kenny RA. Midodrine: a role in the management of neurocardiogenic syncope. Heart 1998;79:45-9.
21. DiGirolamo E, Di Iorio C, Sabatini P, Leonzio L, Barbone C, Barsotti A. Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1999;33:1227-30.
22. Da Costa D, McIntosh S, Kenny RA. Benefits of fludrocortisone in the treatment of symptomatic vasodepressor carotid sinus syndrome. Br Heart J 1993;69:308-10.
23. Scott WA, Pongiglione G, Bromberg BI, Schaffer MS, Deal BJ, Fish FA, et al. Randomized comparison of atenolol and fludrocortisone acetate in the treatment of pediatric neurally mediated syncope. Am J Cardiol 1995;76:400-2.
24. Hussain RM, McIntosh SJ, Lawson J, Kenny RA. Fludrocortisone in the treatment of hypotensive disorders in the elderly. Heart 1996;76:507-9.
25. Connolly SJ, Sheldon R, Roberts RS, Gent M. The North American vasovagal pacemaker study (VPS): a randomized trial of permanent cardiac pacing for the prevention of vasovagal syncope. J Am Coll Cardiol 1999;33:16-20.